ExpreS2ion Biotech Holding AB (publ) (STO:EXPRS2)
Sweden · Delayed Price · Currency is SEK | Market Cap | 5.54M -92.5% |
| Revenue (ttm) | 16.12M +74.7% |
| Net Income | -36.24M |
| EPS | -10.26 |
| Shares Out | 3.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 94,181 |
| Open | 1.525 |
| Previous Close | 1.590 |
| Day's Range | 1.525 - 1.585 |
| 52-Week Range | 1.525 - 28.550 |
| Beta | 2.16 |
| Analysts | n/a |
| Price Target | 6.00 (+282.17%) |
| Earnings Date | Jun 4, 2026 |
About STO:EXPRS2
ExpreS2ion Biotech Holding AB (publ), a biotechnology company, develops vaccines and biologics products to address critical unmet medical needs in the Nordics and internationally. The company’s lead asset is ES2B-C001, a therapeutic vaccine which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2. It is also developing ES2B-I002, a cytomegalovirus vaccine program to treat infectious diseases, as well as vaccines for Nipah virus, Malaria, and influenza. In addition, the company offers a huma... [Read more]
Financial Performance
In 2025, STO:EXPRS2's revenue was 12.21 million, an increase of 56.00% compared to the previous year's 7.83 million. Losses were -38.09 million, 5.68% more than in 2024.
Financial StatementsNews
ExpreS2ion Biotech Holding AB Earnings Call Transcript: Q1 2026
Q1 saw strong clinical and financial progress, with ES2B-C001 showing positive safety and immunogenicity, operating income up 132% year-over-year, and liquidity boosted by a rights issue. Multiple milestones are expected in oncology and infectious disease programs over the next year.
ExpreS2ion Biotech Holding AB Quarterly report: Q1 2026
ExpreS2ion Biotech Holding AB has published its Q1 2026 quarterly earnings report on May 28, 2026.
ExpreS2ion Biotech Holding AB Slides: Q1 2026
ExpreS2ion Biotech Holding AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 28, 2026.
ExpreS2ion Biotech Holding AB Earnings Call Transcript: Q4 2025
Q4 and full year 2025 saw strong clinical and financial progress, with income up 56% year-on-year and a significantly improved underlying net loss. The pipeline advanced in oncology and infectious diseases, supported by grant funding and a solid cash position for 2026 milestones.
ExpreS2ion Biotech Holding AB Quarterly report: Q4 2025
ExpreS2ion Biotech Holding AB has published its Q4 2025 quarterly earnings report on February 19, 2026.
ExpreS2ion Biotech Holding AB Slides: Q4 2025
ExpreS2ion Biotech Holding AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 19, 2026.
ExpreS2ion Biotech Holding AB Transcript: Life Science Summit 2025
A novel HER2-targeted therapeutic vaccine is advancing through phase I trials, showing promising immune responses and potential to address high unmet needs in breast cancer. The therapy targets a large, growing market and is supported by a strong pipeline, recent partnerships, and a solid financial position.
ExpreS2ion Biotech Holding AB Earnings Call Transcript: Q3 2025
Q3 saw strong execution with increased income, improved net loss, and expanded global partnerships, including a major malaria vaccine license. Cash runway extends into Q2 2026, with key clinical and partnership milestones expected over the next 18 months.
ExpreS2ion Biotech Holding AB Quarterly report: Q3 2025
ExpreS2ion Biotech Holding AB has published its Q3 2025 quarterly earnings report on November 13, 2025.
ExpreS2ion Biotech Holding AB Slides: Q3 2025
ExpreS2ion Biotech Holding AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 13, 2025.
ExpreS2ion Biotech Holding AB Transcript: Investing in Life Science 2025
A novel immunotherapy targeting all HER2 domains in breast cancer shows strong preclinical and early clinical results, with phase I data progressing and broader market expansion planned. Strategic partnerships and prudent financial management support a EUR 5 billion+ addressable market.
ExpreS2ion Biotech Holding AB Earnings Call Transcript: Q2 2025
Strong pipeline progress with the breast cancer vaccine trial expanding and new partnerships in malaria and influenza. H1 2025 income rose 61% year-over-year, with a SEK 49 million cash position providing runway through Q1 2026. Key data readouts expected in 2026.
ExpreS2ion Biotech Holding AB Quarterly report: Q2 2025
ExpreS2ion Biotech Holding AB has published its Q2 2025 quarterly earnings report on August 21, 2025.
ExpreS2ion Biotech Holding AB Slides: Q2 2025
ExpreS2ion Biotech Holding AB has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 21, 2025.